Mutual of Omaha Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,150 shares of the medical instruments supplier’s stock, valued at approximately $224,000.

Several other institutional investors have also made changes to their positions in BDX. Beese Fulmer Investment Management Inc. raised its stake in Becton, Dickinson and by 2.7% in the first quarter. Beese Fulmer Investment Management Inc. now owns 26,022 shares of the medical instruments supplier’s stock valued at $4,773,000 after buying an additional 688 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Becton, Dickinson and by 188.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 26,494 shares of the medical instruments supplier’s stock valued at $4,881,000 after buying an additional 17,298 shares in the last quarter. Carderock Capital Management Inc. raised its stake in Becton, Dickinson and by 0.5% in the first quarter. Carderock Capital Management Inc. now owns 13,499 shares of the medical instruments supplier’s stock valued at $2,476,000 after buying an additional 69 shares in the last quarter. Pinnacle Bank purchased a new stake in Becton, Dickinson and during the first quarter valued at about $192,000. Finally, Doyle Wealth Management purchased a new stake in Becton, Dickinson and during the first quarter valued at about $434,000. 75.71% of the stock is currently owned by institutional investors.

Shares of Becton, Dickinson and Company (BDX) traded up 1.08% during midday trading on Friday, reaching $200.36. The company’s stock had a trading volume of 1,251,199 shares. The company has a market capitalization of $45.59 billion, a price-to-earnings ratio of 58.02 and a beta of 1.05. The stock has a 50 day moving average price of $198.90 and a 200-day moving average price of $187.70. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. During the same quarter last year, the company earned $2.35 EPS. Equities research analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.46%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

TRADEMARK VIOLATION WARNING: “1,150 Shares in Becton, Dickinson and Company (BDX) Acquired by Mutual of Omaha Bank Wealth Management” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/13/1150-shares-in-becton-dickinson-and-company-bdx-acquired-by-mutual-of-omaha-bank-wealth-management.html.

Several research firms recently issued reports on BDX. Bank of America Corporation reissued a “buy” rating and set a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research report on Monday, July 17th. Barclays PLC reissued an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday. Finally, Cowen and Company reissued an “outperform” rating and set a $230.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $195.79.

In related news, VP Jeffrey S. Sherman sold 28,765 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the completion of the transaction, the vice president now owns 70,821 shares in the company, valued at approximately $13,171,289.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders have sold a total of 44,019 shares of company stock valued at $8,368,433 in the last 90 days. 1.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.